Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - March 2013


18th Congress of The European Association of Hospital Pharmacists (EAHP)

13 Mar 2013 - 15 Mar 2013 - Palais des Congrès, Paris, France



Bookmark and Share


The European Association of Hospital Pharmacists (EAHP) is a working community of national associations of hospital pharmacists. Membership is increasing each year and, at present, EAHP represents the interest of over 21,000 hospital pharmacists in 32 countries all over Europe.

EAHP’s annual congress is the largest congress for hospital pharmacy in Europe and is attended by professionals from over 50 countries. Approximately 4.000 hospital pharmacists are expected to attend the 18th Congress of the EAHP next 13-15 March 2013 at the Palais des Congrès in Paris, France.

“Improving patient outcomes – a shared responsibility”  will be the theme for the presentations at the Paris 2013 EAHP Congress. A scientific programme including 3 keynote presentations, 13 seminars open for interactions with the speakers and 3 interactive workshops will offer participants the unique opportunity to meet, network and share expertise. EAHP’s industry partners have also committed to conducting satellite symposia highlighting important new developments important to hospital pharmacy.

EAHP’s Congress is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education, as well as by some of its national member associations according to the different national accreditation systems.

REGISTRATION OPEN 1 AUGUST 2012:
Register online to attend the EAHP 18th Congress.

CALL FOR ABSTRACTS: 
Deadline for submission is 15 October 2012.  Original contributions from all fields of hospital pharmacy are welcomed for poster presentation. 

For further information, please visit the website, where you will also be able to find more details on our scientific programme.

The registration fees are set follows :

 

— before 1 December 2012  € 600

— beginning 1 December 2012 € 700

— beginning 1 February 2013 € 800

 

Registration fee includes access to all sessions, the opening reception, the exhibition, lunches on Wednesday, Thursday, Friday and coffee/tea during official breaks.

 

Registration fee includes 19,6% VAT until 1 October and 21,2% afterwards according to French law.



Further information
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!